RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. With a remarkable heritage in the field, the company has achieved significant milestones, including being among one of the first in the world to produce clinical-grade human pluripotent stem cells. In collaboration with their partners, RoslinCT also developed the first CRISPR-edited cell therapy product for a major inherited disorder, taking it from early development to commercialization. RoslinCT is also to perform technology transfer and commercial manufacture of Omisirge®, a commercial product for the treatment of hematologic malignancies, at RoslinCT’s cell therapy manufacturing facility in Hopkinton, MA.
Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation.
MassBio Member Spotlight: RoslinCT
Location: Hopkinton, MA and Edinburgh, Scotland
Website: roslinct.com
Leadership:
- Peter Coleman | CEO
- Geoffrey Hamilton-Fairley | Executive Chairman
- Gary Menzel | President
- Lee Warren | CFO
- Dean Morris | COO US
- Jane Fraser | COO UK
- Jessica Carmen | CCO
- Kathy Burri Head of Quality | US
- Lynda Brown Head of Quality | UK
- Kevin Bruce | Chief Technology Officer
- Barbara Ressler | Head of Process Sciences
- Rebecca Street-Howard | Head of Digital Operations
Business Type: Global Advanced Cell & Gene Therapy CDMO
